The Vaccine Formulation Laboratory: a platform for access to adjuvants

Area of Science:

• Vaccinology
• Immunology
• Biotechnology

Background:

• Adjuvants are crucial for enhancing vaccine immunogenicity and enabling dose-sparing.
• Limited access to adjuvants and formulation expertise hinders public sector vaccine research.
• The World Health Organization established a Vaccine Formulation Laboratory to address these challenges.

Purpose of the Study:

• To facilitate the transfer of adjuvant and formulation technology.
• To support academic institutions, biotechnology companies, and manufacturers in developing countries.
• To enhance global vaccine production capacity, particularly for pandemic influenza.

Main Methods:

• Establishment of the Vaccine Formulation Laboratory at the University of Lausanne.
• Transfer of adjuvant and formulation technology free of intellectual property rights.
• Collaboration with Bio Farma, an Indonesian vaccine manufacturer, for pandemic influenza vaccine production.

Main Results:

• Initiation of technology transfer to Bio Farma for increased domestic pandemic influenza vaccine production.
• Empowerment of developing countries' vaccine manufacturers with advanced formulation capabilities.
• Strengthening national pandemic influenza preparedness plans through enhanced local production.

Conclusions:

• The Vaccine Formulation Laboratory plays a vital role in democratizing access to essential vaccine technologies.
• Accessible adjuvant formulation expertise is critical for advancing global public health and pandemic preparedness.
• International collaborations are key to building robust domestic vaccine manufacturing capabilities.